K. David Voduc, MD FRCPC
Clinical Assistant Professor
University of British Columbia (UBC)
Active Staff: British Columbia Cancer Agency (BCCA) – Vancouver Centre*
Director of Breast Radiation Oncology (BCCA) – Vancouver Centre*
Hospital Authority: Provincial Health Services
600 West 10th Avenue
Vancouver, BC V5Z 4E6
Phone: 604.877.6000 Fax: 604.877.0505
Major Clinical Focus – Breast and Gastrointestinal Oncology
• Doctor of Medicine, University of Toronto, Canada, 2000
• Bachelor of Science, McGill University, Canada, 1996
• Fellow of The Royal College of Physicians of Canada (Radiation Oncology), The Royal College of Physicians and Surgeon of Canada, 2005
• Research Fellowship at the Genetic Pathology Evaluation Centre, University of British Columbia
Biographic Summary ( Background, Academic Interests and Activities, Clinical Activities )
David Voduc has been a radiation oncologist at the BC Cancer Agency since 2006. His clinical focus is breast and gastrointestinal oncology. David Voduc completed a research fellowship in molecular epidemiology at the Genetic Pathology Evaluation Centre at the University of British Columbia. His research has focused primarily on breast cancer subtyping using immunohistochemistry, and using novel immunohistochemical biomarkers to improve clinical decision-making. Applying this knowledge to the clinic will hopefully lead to more selective use of adjuvant therapies, improved survival outcomes, and reduced treatment-related morbidity. David Voduc is also a member of the Breast Cancer Outcomes Unit and is the current chair of the collaborative GPEC-BCOU group (www.gpec.ubc.ca). He is an active member of the BC Cancer Agency Research Ethics Board and the Research and Clinical Trials Advisory Group.
1. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Davies S, Stijleman IJ, Davis C, Ebbert MT, Parker JS, Ellis MJ, Bernard PS, Perou CM, Nielsen TO. Clin Cancer Res. 2012 Apr 15;18(8):2402-12. Epub 2012 Feb 20.
2. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ. Clin Cancer Res. 2010 Nov 1;16(21):5222-32. Epub 2010 Sep 13.
3. Metastatic behavior of breast cancer subtypes. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. J Clin Oncol. 2010 Jul 10;28(20):3271-7. Epub 2010 May 24.
4. HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. Chiu CG, Masoudi H, Leung S, Voduc DK, Gilks B, Huntsman DG, Wiseman SM. Ann Surg. 2010 Jun;251(6):1107-16.
5. Breast cancer subtypes and the risk of local and regional relapse. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. J Clin Oncol. 2010 Apr 1;28(10):1684-91. Epub 2010 Mar 1.
6. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. J Natl Cancer Inst. 2009 May 20;101(10):736-50. Epub 2009 May 12.
7. Supervised risk predictor of breast cancer based on intrinsic subtypes. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. J Clin Oncol. 2009 Mar 10;27(8):1160-7. Epub 2009 Feb 9.
8. Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options. Voduc D, Nielsen TO. Clin Breast Cancer. 2008 Dec;8 Suppl 4:S171-8. Review.
9. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. Voduc D, Nielsen TO, Cheang MC, Foulkes WD. Hum Pathol. 2008 Oct;39(10):1431-7. Epub 2008 Jul 11.
10. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Clin Cancer Res. 2008 Mar 1;14(5):1368-76.
11. Tissue microarrays in clinical oncology. Voduc D, Kenney C, Nielsen TO. Semin Radiat Oncol. 2008 Apr;18(2):89-97. Review.
12. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Voduc D, Cheang M, Nielsen T. Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):365-73.
* The British Columbia Cancer Agency (BCCA)-Vancouver Centre (VC) is the largest academic cancer centre for the BCCA, located in downtown Vancouver and treating about one third of the radiation oncology cancer patients in the Province of BC. Over 4360 cancer patients are seen each year in the radiation oncology department. There are 20 Radiation Oncology (RO) physician faculty with full disease site specialization and clinical programs of excellence, 2 General Practice (Internist) Oncology Physicians, 3 Clinical Fellows and 10 RO residents. The BCCA-Vancouver Centre also has 17 physicists and a graduate training program in physics, 15 nurses, >60 radiation therapists clerks, secretaries and many others within radiation oncology. General capabilities include 9 Linacs (including Truebeam), 1 cobalt, VMAT (first developed in the BCCA-VC), IMRT, SBRT, IGRT, HDR and LDR brachytherapy suites, and Protons (at the TRIUMF centre). The Vancouver Centre radiation oncology department conducts all levels of research (basic, translational, clinical, population), and is the main educational institution in BC for the training of graduate (residents) and undergraduate (medical) students. The interdisciplinary Radiation Oncology team is part of the even larger multidisciplinary and provincial teams.